Max Sych — or "Mighty Max" — has spinal muscular atrophy Type 2, a rare, progressive disorder that affects about one in 6,000 babies.

The drug's approval is exciting news for two Alberta families who have been trying to fundraise millions of dollars to access the treatment for SMA.

Two Alberta families are celebrating early Christmas miracles this week. Kaysen Martin and Harper Hanki both received IV gene-therapy treatments.

A family is urgently trying to raise $2.8 million to give their son a potentially life-changing drug that could help him with his spinal muscular atrophy.

Harper Hanki, who is just over a year old, was diagnosed with spinal muscular atrophy Type 1 (SMA 1) when she was just seven months old.

A little girl from Spruce Grove, Alta., is bringing people from across the province together in a fight for a multi-million-dollar lifesaving treatment.

Lucy Van Doormaal received a dose of Zolgensma at B.C. Children’s Hospital on Sept. 9.

The drug company Novartis/AveXis, which makes the very expensive drug Zolgensma, gifts a treatment to someone about every two weeks. 

One-year-old Aryan Deol has spinal muscular atrophy (SMA), a condition that causes muscular weakness and atrophy.

In a statement, Lucy's parents said they don't have a confirmed date for the treatment yet but it will likely be early September.